Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes
AH Cincotta, AH Meier, M Cincotta Jr - Expert opinion on …, 1999 - Taylor & Francis
Bromocriptine, a potent dopamine D2 receptor agonist, has been shown to reduce insulin
resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and …
resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and …
Protective effects of zingerone on high cholesterol diet-induced atherosclerosis through lipid regulatory signaling pathway
X Geng, H Liu, Q Yuwen, J Wang… - Human & …, 2021 - journals.sagepub.com
Aim: A high cholesterol diet (HCD) is known to cause metabolic dysregulation, oxidative
stress, cardiovascular diseases and atherogenesis. Zingerone is a pharmacologically active …
stress, cardiovascular diseases and atherogenesis. Zingerone is a pharmacologically active …
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
Diabetes is a global health concern that has affected almost 415 million people globally.
Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA) …
Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA) …
[PDF][PDF] A comparative study of antidiabetic effect of bromocriptine and metformin in alloxan-induced diabetic rats
AK Pathak, PK Sinha, J Sharma - International Journal of Pharmaceutical …, 2013 - Citeseer
Bromocriptine mesylate quick release formulation has recently been approved by FDA for
the treatment of diabetes mellitus. Till now it has been mainly known for its use in …
the treatment of diabetes mellitus. Till now it has been mainly known for its use in …
Clozapine worsens glucose intolerance, nonalcoholic fatty liver disease, kidney damage, and retinal injury and increases renal reactive oxygen species production …
Clozapine is widely employed in the treatment of schizophrenia. Compared with that of
atypical first-generation antipsychotics, atypical second-generation antipsychotics such as …
atypical first-generation antipsychotics, atypical second-generation antipsychotics such as …
Vincristine attenuates isoprenaline-induced cardiac hypertrophy in male Wistar rats via suppression of ROS/NO/NF-қB signalling pathways
Vincristine (VCR), a vinca alkaloid with anti-tumor and anti-oxidant properties, is acclaimed
to possess cardioprotective action. However, the molecular mechanism underlying this …
to possess cardioprotective action. However, the molecular mechanism underlying this …
The effect of 2-month bromocriptine treatment on the activity of the adenylyl cyclase signaling system in the myocardium and testes of rats with type 2 diabetes
KV Derkach, VM Bondareva, IV Moiseyuk… - Cell and Tissue …, 2015 - Springer
Cardiovascular diseases and dysfunctions of the reproductive system are common
complications of type 2 diabetes (T2D), and, therefore, development of new approaches for …
complications of type 2 diabetes (T2D), and, therefore, development of new approaches for …
Bromocriptine reduces steatosis in obese rodent models
LM Davis, Z Pei, MA Trush, LJ Cheskin… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: Obesity is a risk factor for glucose intolerance, steatosis, and
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …
oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have …
Effect of Clonidine (an antihypertensive drug) treatment on oxidative stress markers in the heart of spontaneously hypertensive rats
NS Nik Yusoff, Z Mustapha… - Oxidative medicine …, 2013 - Wiley Online Library
Hypertension is a risk factor for several cardiovascular diseases and oxidative stress
suggested to be involved in the pathophysiology. Antihypertensive drug Clonidine action in …
suggested to be involved in the pathophysiology. Antihypertensive drug Clonidine action in …
[HTML][HTML] Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
M Niafar, L Pourafkari, K Shahsavarinia… - … of Cardiovascular and …, 2016 - ncbi.nlm.nih.gov
Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic
control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus …
control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus …